Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 3, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)

Company name: Mochida Pharmaceutical Co., Ltd.
Listing: Tokyo Stock Exchange
Securities code: 4534
URL: https://www.mochida.co.jp/english/
Representative: (Name) Naoyuki Mochida (Title) Representative Director, President
Inquiries: (Name) Kenichi Miyamoto (Title) Head of Finance & Accounting Department
Telephone: +81-3-3358-7211
Scheduled date to commence dividend payments: -
Preparation of supplementary material on financial results: None
Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	31,719	19.1	3,564	38.5	4,187	50.5	3,178	67.8
June 30, 2025	26,631	4.8	2,572	17.5	2,783	17.6	1,894	21.8

Note: Comprehensive income For the three months ended June 30, 2026: ¥1,702 million [(9.2)%]
For the three months ended June 30, 2025: ¥1,875 million [121.1%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	89.77	-
June 30, 2025	53.43	-

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2026	181,422	140,293	77.3
March 31, 2026	182,720	140,326	76.8

Reference: Equity
As of June 30, 2026: ¥140,293 million
As of March 31, 2026: ¥140,326 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	-	40.00	-	40.00	80.00
Fiscal year ending March 31, 2027	-				
Fiscal year ending March 31, 2027 (Forecast)		42.50	-	42.50	85.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	126,000	7.7	10,500	3.5	12,500	11.6	10,000	26.5	282.86

Note: Revisions to the financial result forecast most recently announced: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None
Newly included: - companies (Company name)
Excluded: - companies (Company name)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement
(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
(ii) Changes in accounting policies due to other reasons: None
(iii) Changes in accounting estimates: None
(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	36,390,000 shares
As of March 31, 2026	36,390,000 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	1,036,263 shares
As of March 31, 2026	940,363 shares

(iii) Average number of shares outstanding during the period (cumulative)

Three months ended June 30, 2026	35,407,904 shares
Three months ended June 30, 2025	35,450,466 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Explanation of the proper use of financial result forecasts and other special matters
The financial result forecasts presented in this document are based on information that is currently available to the Company as of the announcement of this document, and the Company does not guarantee to achieve them. In addition, actual financial results may differ significantly from these forecasts due to a wide range of factors.

Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	28,064	25,415
Accounts receivable - trade, and contract assets	36,478	37,288
Securities	2,993	2,992
Merchandise and finished goods	20,126	19,222
Work in process	2,511	2,989
Raw materials and supplies	13,484	13,908
Other	15,362	4,484
Total current assets	119,021	106,303
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	6,520	6,426
Machinery, equipment and vehicles, net	1,582	1,529
Land	6,046	6,046
Other, net	2,152	2,208
Total property, plant and equipment	16,302	16,210
Intangible assets	1,121	1,046
Investments and other assets		
Investment securities	39,228	37,295
Retirement benefit asset	699	692
Long-term prepaid expenses	5,068	18,340
Deferred tax assets	820	1,081
Other	458	452
Total investments and other assets	46,275	57,862
Total non-current assets	63,699	75,119
Total assets	182,720	181,422

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Accounts payable - trade	9,779	10,213
Electronically recorded obligations - operating	998	994
Income taxes payable	2,970	1,805
Provision for bonuses	2,409	1,061
Other provisions	165	109
Other	11,411	12,788
Total current liabilities	27,734	26,972
Non-current liabilities		
Long-term borrowings	10,000	10,000
Retirement benefit liability	3,337	3,345
Other	1,322	811
Total non-current liabilities	14,659	14,156
Total liabilities	42,394	41,129
Net assets		
Shareholders' equity		
Share capital	7,229	7,229
Capital surplus	1,871	1,871
Retained earnings	121,251	123,012
Treasury shares	(3,270)	(3,587)
Total shareholders' equity	127,081	128,525
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	12,412	10,994
Foreign currency translation adjustment	(30)	(25)
Remeasurements of defined benefit plans	861	798
Total accumulated other comprehensive income	13,244	11,768
Total net assets	140,326	140,293
Total liabilities and net assets	182,720	181,422

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Net sales	26,631	31,719
Cost of sales	13,005	17,031
Gross profit	13,626	14,688
Selling, general and administrative expenses	11,053	11,123
Operating profit	2,572	3,564
Non-operating income		
Interest income	15	14
Dividend income	236	283
Share of profit of entities accounted for using equity method	—	377
Other	33	37
Total non-operating income	285	713
Non-operating expenses		
Interest expenses	0	43
Share of loss of entities accounted for using equity method	18	—
Foreign exchange losses	49	43
Other	6	3
Total non-operating expenses	75	90
Ordinary profit	2,783	4,187
Extraordinary income		
Gain on sale of investment securities	—	687
Total extraordinary income	—	687
Extraordinary losses		
Loss on sale and retirement of non-current assets	0	0
Loss on disposal of removal cost assets	—	9
Total extraordinary losses	0	9
Profit before income taxes	2,782	4,866
Income taxes	888	1,687
Profit	1,894	3,178
Profit attributable to owners of parent	1,894	3,178

Quarterly Consolidated Statements of Comprehensive Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Profit	1,894	3,178
Other comprehensive income		
Valuation difference on available-for-sale securities	19	(1,448)
Foreign currency translation adjustment	—	5
Remeasurements of defined benefit plans, net of tax	(37)	(54)
Share of other comprehensive income of entities accounted for using equity method	—	22
Total other comprehensive income	(18)	(1,476)
Comprehensive income	1,875	1,702
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,875	1,702

Sales of Major Products

(Three months ended June 30, 2026)

(Billions of yen)

Products		Fiscal year ended March 31, 2026		Fiscal year ending March 31, 2027		Three months Y o Y change
		Apr-Jun	Apr-Mar	Apr-Jun	Apr-Mar forecast	
Treatment for ulcerative colitis	Lialda	4.0	16.8	4.6	17.4	+ 15%
Treatment for chronic constipation	Goofice	2.2	9.0	2.3	9.7	+ 7%
Treatment for gout and hyperuricemia	Urece	1.3	6.3	1.7	7.3	+ 37%
Treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease	Treprost	1.3	6.1	1.7	7.0	+ 31%
Drug for hyperlipidemia and arteriosclerosis obliterans	Epadel	1.1	4.6	1.1	5.3	+ 1%
Anticoagulant agent	Heparin Sodium MOCHIDA	0.3	1.4	0.4	1.7	+ 16%
Treatment for ulcerative colitis	Cortiment	0.1	0.6	0.1	0.8	+ 11%
Generic drugs		7.7	35.1	10.4	42.7	+ 35%
Therapeutic agent for endometriosis, adenomyosis and dysmenorrhea	Dienogest	2.8	12.2	3.1	13.1	+ 13%
Skin Care Products		1.9	7.9	2.2	8.3	+ 19%

Notes:

Sales figures are rounded down to the nearest ¥100 million. Year-on-year change rates are calculated using figures before rounding.

Treprost sales include sales of Treprost Inhalation Solution and Treprost Injection.

Epadel sales include sales of Epadel EM, Epadel S, and Epadel Capsules.

Development Pipeline

【Ethical drug】

Development code <Generic name>	Stage	Indications	Formu-lation	Remarks <Development country>
MD-712 <treprostinil>	Filed	Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease	Dry Powder Inhaler	Licensed-in from United Therapeutics Corporation In-house development <Japan>
* FYU-981 <dotinurad>	Filed	Gout and hyperuricemia (pediatric indication)	Oral	Co-development with FUJI YAKUHIN CO., LTD. <Japan> † Succession to the manufacturing and marketing approval for Urece, the brand name of FYU-981, in June 2026
HLC-001	Phase III	Non-infectious pulmonary complications after hematopoietic stem cell transplantation	Injection	Cellular therapy product Co-development with Human Life CORD Japan, Inc. <Japan>
MD-352 <dienogest formulation>	Phase II/III	Dysmenorrhea	Oral	In-house development <Japan>

【Medical device】

Development code <Product name>	Stage	Intended use or indications	Remarks <Development country>
dMD-002	Therapeutic confirmatory study	Repair of cavernous nerve injury	In-house development <Japan>
dMD-003	Therapeutic confirmatory study	Prevention of post-operative adhesion	In-house development <Japan>
dMD-002	Therapeutic exploratory study	Repair of cavernous nerve injury	In-house development <U.S.>

Stages of medical devices are classified into "Therapeutic exploratory study" and "Therapeutic confirmatory study".

* Updates from May 15, 2026